Low dose tamoxifen and other approaches to improve chemoprevention uptake

Brief Synopsis:

Results of a phase III trial of low-dose Tamoxifen (baby TAM) in preinvasive disease will be reviewed, including the rationale for dose reduction and results of subgroups analysis to better define responders and non responders.

Results of babyTAM will be put in context of additional strategies to increase preventive therapy update, including results of topical Tamoxifen metabolite trials and current status of ongoing studies. New ideas for clinical prevention research will be discussed to move the field forward.